DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucolipidosis type III, alpha/beta — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucolipidosis type III, alpha/beta maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucolipidosis type iii, alpha/beta is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta (GNPTAB) — GNPTAB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ud1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9BGF · 2.9 Å · ligand URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE (UD1). Experimental structure, not a prediction.
What the evidence adds up to
Mucolipidosis type III alpha/beta is an autosomal recessive lysosomal disease caused by deficiency of GlcNAc-1-phosphotransferase, the alpha/beta subunits of which are encoded by the GNPTAB gene. The enzyme defect disrupts generation of the mannose 6-phosphate marker on lysosomal hydrolases, leading to defective lysosomal targeting and intracellular accumulation of non-degraded material. Clinical severity depends on residual GlcNAc-1-phosphotransferase activity, which distinguishes the milder type III from the severe neonatal-onset type II disease. A two-year-old Chinese boy with mucolipidosis III alpha/beta presented with poor weight gain, microcephaly, increased tone, joint contractures, coarse facial features, kypho-lordosis, pectus carinatum, and umbilical hernia. He had relatively mild developmental delay compared to severe type I and type II mucopolysaccharidosis and no macrocephaly. Lysosomal enzyme activity assays showed elevated α-iduronidase, iduronate sulfatase, galactose-6-sulphate sulphatase, arylsulfatase B, and α-hexosaminidase activities. Genetic testing confirmed he harboured the common splice site mutation c.2715+1G>A and the nonsense variant c.2404C>T (p.Q802*) in GNPTAB. The nonsense variant c.2404C>T has been recently reported and this case contributes to the genotype-phenotype spectrum.
A separate study of three Brazilian patients with mucolipidosis III gamma (a different subtype caused by deficiency of the gamma subunit of GlcNAc-1-phosphotransferase) evaluated humoral immune response. Previous data had indicated that MLII patients have a functionally impaired immune system that predisposes them to infections. In these three ML III gamma patients, the data suggested that residual GlcNAc-1-phosphotransferase activity is enough to allow targeting of the lysosomal enzymes required for maintenance of B-cell functions. No numbers of patients beyond three, no quantitative immune measures, and no infection rates were reported in that abstract.
No drug treatment, repurposed or otherwise, is mentioned in either abstract. No clinical trial of any therapy for mucolipidosis III alpha/beta is described. What is missing is any evidence that a drug can alter the course of the disease; the literature so far is limited to case reports and small immunological observations. There are no data on whether residual enzyme activity in type III patients can be augmented pharmacologically, no trial designs that test a specific compound, and no patient stratification beyond genotype. Funding for preclinical drug screening or for a natural history study that could support a future trial is not reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Endocrinology and Metabolism · 2012 · 17 citations
Mucolipidosis type II (I-cell disease) masquerading as rickets: two case reports and review of literature
AbstractMucolipidosis type II (ML II) is a rare disease. Its diagnosis is often missed, as it may present with rickets-like picture. ML II and rickets both may have physical findings including fractures, kyphoscoliosis, as well as similar biochemical and radiographic studies. Their similarities often lead to delayed diagnosis and treatment for ML II patients. We describe two cases of ML II, both confirmed by DNA sequencing of the GNPTAB gene and by plasma enzymes assays. The second patient had a much better outcome because of prompt diagnosis and was able to undergo bone marrow transplant as a result. We also review all literature in the English language for cases of ML II presenting with rickets-like pictures.
Humoral immune response in adult Brazilian patients with Mucolipidosis III gamma
AbstractAbstract Mucolipidosis II and III (ML II and III) alpha/beta and ML III gamma are lysosomal diseases caused by GlcNAc-1-phosphotransferase deficiency. Previous data indicate that MLII patients have functionally impaired immune system that contributes to predisposition to infections.We evaluated the immunological phenotype of three Brazilian patients with ML III gamma. Our data suggest that the residual activity of GlcNAc-1-phosphotransferase in patients with ML III gamma is enough to allow the targeting of the lysosomal enzymes required for B-cell functions maintenance.
GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report
AbstractAbstract Background Mucolipidosis alpha/beta is an inborn error of metabolism characterized by deficiency of GlcNAc-1-phosphotransferase, in which essential alpha/beta subunits are encoded by the GNPTAB gene. The autosomal recessive condition is due to disruptions of hydrolase mannose 6-phosphate marker generation, defective lysosomal targeting and subsequent intracellular accumulation of non-degraded material. Clinical severity depends on residual GlcNAc-1-phosphotransferase activity, which distinguishes between the milder type III disease and the severe, neonatal onset type II disease. Case presentation We report the clinical, biochemical and genetic diagnosis of mucolipidosis III alpha/beta in a two-year-old Chinese boy who initially presented with poor weight gain, microcephaly and increased tone. He was confirmed to harbor the common splice site mutation c.2715 + 1G > A and the nonsense variant c.2404C > T (p.Q802*). Clinically, the patient had multiple phenotypic features typical of mucopolysaccharidosis including joint contractures, coarse facial features, kypho-lordosis, pectus carinatum and umbilical hernia. However, the relatively mild developmental delay compared to severe type I and type II mucopolysaccharidosis and the absence of macrocephaly raised the possibility of the less commonly diagnosed mucolipidosis alpha/beta. Critical roles of lysosomal enzyme activity assay, which showed elevated α-iduronidase, iduronate sulfatase, galactose-6-sulphate sulphatase, arylsulfatase B and α-hexosaminidase activities; and genetic study, which confirmed the parental origin of both mutations, were highlighted. Conclusions The recently reported nonsense variant c.2404C > T in the GNPTAB gene is further recognized and this contributes to the genotype-phenotype spectrum of mucolipidosis alpha/beta.
GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report
AbstractAbstract Background Mucolipidosis alpha/beta is an inborn error of metabolism characterized by deficiency of GlcNAc-1-phosphotransferase, in which essential alpha/beta subunits are encoded by the GNPTAB gene. The autosomal recessive condition is due to disruptions of hydrolase mannose 6-phosphate marker generation, defective lysosomal targeting and subsequent intracellular accumulation of non-degraded material. Clinical severity depends on residual GlcNAc-1-phosphotransferase activity, which distinguishes between the milder type III disease and the severe, neonatal onset type II disease. Case presentation We report the clinical, biochemical and genetic diagnosis of mucolipidosis III alpha/beta in a two-year-old Chinese boy who initially presented with poor weight gain, microcephaly and increased tone. He was confirmed to harbor the common splice site mutation c.2715 + 1G > A and the nonsense variant c.2404C > T (p.Q802*). Clinically, the patient had multiple phenotypic features typical of mucopolysaccharidosis including joint contractures, coarse facial features, kypho-lordosis, pectus carinatum and umbilical hernia. However, the relatively mild developmental delay compared to severe type I and type II mucopolysaccharidosis and the absence of macrocephaly raised the possibility of the less commonly diagnosed mucolipidosis alpha/beta. Critical roles of lysosomal enzyme activity assay, which showed elevated α-iduronidase, iduronate sulfatase, galactose-6-sulphate sulphatase, arylsulfatase B and α-hexosaminidase activities; and genetic study, which confirmed the parental origin of both mutations, were highlighted. Conclusions The recently reported nonsense variant c.2404C > T in the GNPTAB gene is further recognized and this contributes to the genotype-phenotype spectrum of mucolipidosis alpha/beta.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
